Brean Capital Downgrades Regeneron Pharma (REGN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Baird Releases Bullish Note on Regeneron (REGN), Eylea Taking Share
January 15, 2013 2:23 PM ESTToday analysts a Baird put out a very bullish note on Regeneron Pharma (NASDAQ: REGN). In the note, analysts reiterated an Outperform rating and raised thier price target to $205.00 (from $176.00). Analyst also noted strong uptake of Eylea, which continues to take share from Lucentis... More
Jefferies Downgrades Regeneron Pharma (REGN) to Hold, Sees Limited Eylea Upside
January 15, 2013 7:12 AM ESTJefferies downgraded Regeneron Pharma (NASDAQ: REGN) from Buy to Hold with a price target of $179.00.
The firm sees limited Eylea upside after conducting another wAMD survey. The firm said the current stock prices adequately reflects anticipated growth. Benefit from potential cmpding driven... More
